Clinical trials: Muscle Invasive Bladder Cancer
Bladder Cancer
Bakircay University Cigli Training and Research Hospital
The aim of the study is to investigate the oncological outcomes of obturator nerve blockade in patients with lateral wall localized non-muscle invasive bladder cancer
- Trial name
- BUCEAH (NCT04683536)
- Testing
- Obturator nerve blockade
- Volunteers
- 106 people
- Sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
High-Risk Non-Muscle Invasive Bladder Cancer
A Phase III Randomised Control Clinical Trial of Radiotherapy With Radiosensitisation Versus Intravesical Bacillus Calmette-Guerin Therapy for High-risk Non-muscle Invasive Bladder Cancer.
In the UK 20,000 people develop urothelial bladder cancer each year with 75-80% having Non-Muscle Invasive Bladder Cancer (NMIBC).
- Trial name
- TRAIN (NCT07268339)
- Testing
- radiotherapy, BCG
- Where
- United Kingdom
- Volunteers
- 328 people
- Sponsor
- The Christie NHS Foundation Trust
Urothelial Bladder Carcinoma, Bladder Carcinoma
Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
Bladder cancer is a significant global and local health concern, and predicting how aggressive a patient's tumor will behave is critical for guiding treatment.
- Conditions
- Urothelial Bladder Carcinoma, Bladder Carcinoma, Non-Muscle-Invasive Bladder Cancer (NMIBC), Muscle-Invasive Bladder Cancer (MIBC)
- Trial name
- NCT07529639
- Volunteers
- 100 people
- Sponsor
- Assiut University
Muscle-invasive Bladder Cancer, Artificial Intelligence
Multi-parametric MRI in Patients of Bladder Cancer
Accurate preoperative detection of muscle-invasive bladder cancer remains a clinical challenge. The investigators aimed to develop and validate a knowledge-guided causal diagnostic network for the detection of muscle-invasive…
- Trial name
- NCT06362330
- Testing
- magnetic resonance imaging
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
NMIBC, MIBC
A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)
This was a multicenter, prospective, non-interventional, observational cohort study, and the enrolled patients were divided into four cohorts: cohort I was patients with high-risk upper tract urothelial carcinoma (UTUC) (pT3-4 or…
- Conditions
- NMIBC, MIBC, UTUC
- Trial name
- NCT06991868
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University First Hospital
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
This is a Phase 3, open-label single-arm trial designed to evaluate the safety and efficacy of NDV-01 (sustained-release gemcitabine-docetaxel) in adult participants with NMIBC with CIS who have failed BCG therapy and who have…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Trial name
- RESCUE (NCT07342517)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Relmada Therapeutics, Inc.
Bladder Cancer
Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging
The goal of this research study is to improve detection of cancer outside of the bladder through genetic testing and improved imaging.
- Trial name
- NCT02203136
- Testing
- Tissue Biopsy, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
Radiation Therapy and Chemotherapy Following Surgery in Treating Patients With Stage II or Stage III Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003642
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- 3 sites in France, Netherlands
- Volunteers
- 43 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Bladder Cancer
Diagnostic Performance of the Vesical Imaging-Reporting and Data System (VI-RADS) in Detecting Muscle-invasive Bladder Tumour (MIBC) in Clinical Practice: Comparison With Transurethral Resection of Bladder Cancer (TURB) and Evaluation of Diagnostic Accuracy According to Tumour Location
VI-RADS was an observational, prospective, multicenter, no profit study. The aim of the study was to clarify the clinical validity of the Vesical Imaging-Reporting and Data System (VI-RADS) for the assessment of muscle invasion…
- Trial name
- VI-RADS (NCT06337591)
- Testing
- VI-RADS
- Where
- 3 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Nazionale di Ricovero e Cura per Anziani
Bladder Cancer
Urine-based Detection of Non-muscle Invasive Bladder
Non-muscle invasive bladder cancer (NMIBC), which comprises approximately 75% of bladder tumors, has the highest recurrence rate of all cancers, with around 70% of the patients developing local recurrences, despite elaborated…
- Trial name
- SOLUSION (NCT03962933)
- Where
- Denmark
- Volunteers
- 196 people
- Sponsor
- Nessn Azawi
Cancer, Bladder, Cystostomy; Complications
Outcome of Perioperative Immune Enhancing Nutrition in Patients Undergoing Radical Cystectomy
The aim of this study is to evaluate the outcome of perioperative immune-nutrition with glutamine, arginine and fish oil in patients undergoing radical cystectomy as regards to enhancement of healing, increasing immunity and…
- Trial name
- NCT05822518
- Testing
- Neo-mune powder (otsuka pharmaceutical), Dipeptiven solution (Fresenius Kabi pharmaceutical)
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Menoufia University
Bladder Cancer
PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer
This study evaluates Patient-derived Tumor-like Cell Clusters (PTC)-guided individualized neoadjuvant therapy in patients with muscle-invasive bladder cancer who are candidates for radical cystectomy.
- Trial name
- NCT07690878
- Testing
- PTC guided individualized neoadjuvant therapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Bladder Cancer
Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer
Patients diagnosed with low risk non-muscle invasive bladder cancer (NMIBC) are at risk of frequent low grade recurrence, which usually necessitates surgical intervention under general anaesthetic.
- Trial name
- CALIBER (NCT02070120)
- Testing
- Mitomycin C, Surgical Management
- Where
- 38 sites in United Kingdom
- Volunteers
- 82 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Bladder (Urothelial, Transitional Cell) Cancer, Nonmuscle Invasive Bladder Cancer
Implications of Post-Operative Irrigation Fluid's Osmolarity on the Recurrence of Non-Muscle Invasive Bladder Cancer Following Transurethral Resection
This randomized controlled trial will evaluate the efficacy of three bladder irrigation solutions - distilled water (DW), normal saline (NS), and hypertonic saline (HS) - as continuous bladder irrigation (CBI) following…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Nonmuscle Invasive Bladder Cancer, Irrigation, Hypertonic Saline
- Trial name
- NCT07279792
- Testing
- Continuous Bladder Irrigation with distilled water, Continuous Bladder Irrigation with normal saline, Continuous Bladder Irrigation with hypertonic saline
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Ain Shams University
Non-muscle-invasive Bladder Cancer
Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study
About 40%-80% of NMIBC recur within 6-12 months when managed with TURBT alone, and 10%-25% of the patient's progress to muscle invasive disease.
- Trial name
- NCT05626101
- Testing
- BCG, Gemcitabine
- Where
- Egypt
- Volunteers
- 280 people
- Sponsor
- Al-Azhar University
Cancer, Bladder
Sensitivity of Multiparametric MRI in Differentiation Between Muscle Invasive and Non-muscle Invasive Urinary Bladder Cancer
Differentiation between non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) is a cornerstone in the treatment plans.Therefore, this study will try to evaluate the sensitivity and reliability of…
- Trial name
- NCT05324033
- Testing
- multiparametric MRI on the bladder, diagnostic cystoscopy +/- TURBT
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Helwan University
Bladder Cancer
RESECT: Improving Quality in TURBT Surgery.
Superficial bladder cancer, known as non-muscle-invasive bladder cancer (NMIBC), is the most common type of bladder cancer. It is expensive to manage and significantly impacts on patients' quality of life.
- Trial name
- RESECT (NCT05154084)
- Testing
- Performance feedback and education
- Where
- United Kingdom
- Volunteers
- 19,505 people
- Sponsor
- British Urology Researchers in Surgical Training
Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC)
Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer
Bladder cancer is a significant global health issue. When the cancer spreads into the muscle layer of the bladder (muscle-invasive bladder cancer), a common treatment is the surgical removal of the bladder (radical cystectomy).
- Conditions
- Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC), Bladder Cancer, Muscle-Invasive Urothelial Bladder Carcinoma
- Trial name
- NCT07525349
- Volunteers
- 100 people
- Sponsor
- Assiut University